Boreal Genomics, now part of PCR Biosystems, is a biotechnology company that specialized in developing and commercializing novel solutions for nucleic acid sample preparation and enrichment. Their core technologies aimed to improve the sensitivity and yield of DNA and RNA from complex and low-input samples, facilitating more accurate downstream applications such as sequencing, PCR, and other molecular diagnostic assays. Their flagship technology, ScaLE (Synchronous Coefficient of drag Alteration and Elution), was designed to extract and purify nucleic acids, particularly from challenging sources like FFPE tissues or bodily fluids, enabling researchers and clinicians to access genetic information that was previously difficult to obtain.
Primary center for research and development of nucleic acid extraction technologies, product development, and initial administrative operations prior to acquisition by PCR Biosystems.
Located in a prominent Canadian biotechnology hub, offering access to a rich ecosystem of research institutions and talent. Facilities likely included specialized laboratories for molecular biology and genomics research.
As a specialized biotech firm, the culture likely emphasized innovation, scientific rigor, collaboration, and a fast-paced environment focused on solving complex biological sample preparation challenges.
The Vancouver HQ was crucial for Boreal Genomics's development of its core ScaLE technology and its efforts to penetrate the genomics market with novel sample prep solutions.
Prior to its acquisition by PCR Biosystems in 2021, Boreal Genomics primarily served the North American and international research markets through direct sales and distribution partnerships for its specialized sample preparation instruments and kits. Post-acquisition, its technologies and expertise have been integrated into PCR Biosystems' global sales, distribution, and support network, significantly expanding their reach to researchers and diagnostic laboratories worldwide.
887 Great Northern Way, Suite 210
Vancouver
British Columbia
Canada
Highperformr Signals uncover buying intent and give you clear insights to target the right accounts at the right time — helping your sales, marketing, and GTM teams close more deals, faster.
As of April 2025, Boreal Genomics' leadership includes:
Boreal Genomics has been backed by several prominent investors over the years, including:
Following the acquisition by PCR Biosystems in July 2021, Boreal Genomics ceased to operate as an independent entity with its own distinct executive team. Key leadership roles were either transitioned into PCR Biosystems or individuals moved to other ventures. Therefore, there are no executive hires or exits specifically for 'Boreal Genomics' as a standalone company in the last 12 months.
Discover the tools Boreal Genomics uses. Highperformr reveals the technologies powering your target accounts — helping your sales, marketing, and GTM teams prioritize smarter and close faster.
Common email formats for Boreal Genomics likely followed standard professional patterns. Given the company's size and domain, [first_initial][last]@borealgenomics.com or [first].[last]@borealgenomics.com were probable.
[first_initial][last]@borealgenomics.com
Format
jadoe@borealgenomics.com
Example
70%
Success rate
PCR Biosystems • July 7, 2021
PCR Biosystems Ltd, the UK-based specialists in DNA and RNA analysis, today announced the acquisition of Boreal Genomics, a leader in nucleic acid extraction and purification technology based in Vancouver, Canada. The acquisition will enable PCR Biosystems to integrate Boreal’s proprietary nucleic acid purification technology with its own advanced PCR and molecular biology reagents....more
GenomeWeb • October 26, 2017
Boreal Genomics has received a CA$1.1 million (US$860,000) grant from Grand Challenges Canada to develop a tuberculosis test based on its ScaLE nucleic acid extraction technology. The project aims to create a rapid, sensitive, and cost-effective molecular diagnostic for TB, particularly for use in resource-limited settings....more
BC Govemment News • June 15, 2015
The B.C. government is providing $250,000 to Vancouver-based Boreal Genomics to help the company develop a rapid, accurate and inexpensive field test for the Ebola virus. The funding will support the adaptation of Boreal's existing nucleic acid extraction technology for Ebola detection....more
See where a company’s workforce is located, by country or region.
View past and recent funding rounds with amounts and investors.
Understand company revenue estimates and financial scale.
Track active roles and hiring trends to spot growth signals.
Discover what a company offers—products, platforms, and solutions.
Get the company’s official SIC and NAICS classifications.
Analyze visitor volume, engagement, and top traffic sources.
Explore LinkedIn, Twitter, and other active social profiles.
Identify top competitors based on similar business traits.
Explore companies in depth — from the tech they use to recent funding, hiring trends, and buyer signals — all in one powerful view.
Highperformr AI helps you surface the right accounts and enrich your CRM with verified company and contact insights, so your teams can prioritize and engage faster.
Thousands of companies, including Boreal Genomics, are just a search away.